Bridgeway Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Bridgeway Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,500	Closed	-$129K	–	1343
2023 Q4	$129K	Hold	10,500	–	–	﹤0.01%	1204
2023 Q3	$101K	Hold	10,500	–	–	﹤0.01%	1230
2023 Q2	$94.5K	Sell	10,500 -10,000	-49%	-$92.2K	﹤0.01%	1264
2023 Q1	$161K	Buy	+20,500	New	+$153K	﹤0.01%	1140
2020 Q2	–	Sell	-60,400	Closed	-$462K	–	1350
2020 Q1	$462K	Hold	60,400	–	–	0.01%	798
2019 Q4	$1.08M	Buy	+60,400	New	+$788K	0.01%	718
2019 Q2	–	Sell	-60,000	Closed	-$1.72M	–	1357
2019 Q1	$1.72M	Hold	60,000	–	–	0.02%	584
2018 Q4	$1.19M	Buy	60,000 +19,000	+46%	+$382K	0.02%	671
2018 Q3	$907K	Hold	41,000	–	–	0.01%	923
2018 Q2	$333K	Hold	41,000	–	–	﹤0.01%	1231
2018 Q1	$389K	Buy	+41,000	New	+$429K	﹤0.01%	1149

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Bridgeway Capital Management's KALV Position: Q1 2024 in Review

Bridgeway Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2024, closing a stake of 10,500 shares — an estimated $129K sold.

Bridgeway Capital Management first reported a position in KALV in Q1 2018 and held it in 11 quarters. The position peaked at $1.72M in Q1 2019. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2024.

Bridgeway Capital Management reported no remaining KalVista Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Bridgeway Capital Management sold 10,500 KalVista Pharmaceuticals shares in Q1 2024, an estimated $129K.
Bridgeway Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2018 and held it in 11 quarters.
Bridgeway Capital Management's KalVista Pharmaceuticals position peaked at $1.72M in Q1 2019.
128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2024.

Based on Bridgeway Capital Management's 13F filing for Q1 2024, filed 15 May 2024.